NASDAQ:LRMR Larimar Therapeutics Q3 2026 Earnings Results & Report $3.14 -0.08 (-2.48%) Closing price 04:00 PM EasternExtended Trading$3.09 -0.05 (-1.46%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Larimar Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$0.29 versus the -$0.3514 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 16, 2026TimeBefore Market OpensConference Call7:30 AM ET Larimar Therapeutics EPS ResultsActual EPS-$0.29Consensus EPS -$0.3514Beat/MissBeat by +$0.0614One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersLarimar Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Larimar Therapeutics Q3 2026 Earnings FAQ Did Larimar Therapeutics beat earnings estimates for Q3 2026? Larimar Therapeutics (NASDAQ:LRMR) reported earnings of -$0.29 per share for Q3 2026, beating the consensus estimate of -$0.3514. The report was announced on Monday, November 16, 2026. Larimar Therapeutics Earnings HeadlinesRegulatory Hurdles Threaten Larimar Therapeutics’ Nomlabofusp BLA and Commercial Launch TimelineNovember 17 at 1:11 AM | tipranks.comLarimar Narrows Q3 Loss; Completes BLA Submission For Nomlabofusp In Friedreich's AtaxiaNovember 16, 2026 | rttnews.comWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 20 at 1:00 AM | Porter & Company (Ad)Larimar Therapeutics Announces Completion of BLA Submission for Nomlabofusp in Friedreich’s AtaxiaNovember 16, 2026 | quiverquant.comQLarimar Therapeutics Reports Third Quarter 2026 Financial and Business UpdateNovember 16, 2026 | globenewswire.comLarimar Therapeutics (NASDAQ:LRMR) Stock Price Crosses Above Fifty Day Moving Average - Should You Sell?November 15, 2026 | americanbankingnews.comSee More Larimar Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Larimar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Larimar Therapeutics and other key companies, straight to your email. Email Address About Larimar TherapeuticsLarimar Therapeutics (NASDAQ:LRMR) is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich's ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar's approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms. Larimar is advancing nomlabofusp toward potential FDA approval. In June 2026, the company submitted the first module of its rolling Biologics License Application (BLA), seeking accelerated approval, with the remaining modules expected to be submitted in the second half of 2026. Larimar also plans to explore additional applications for its protein-delivery technology. Its shares trade on the Nasdaq under the symbol LRMR. View Larimar Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.